Intelligence Feed event · Equity · 2026-10-07

    Oculis to Present Licaminlimab at Eyecelerator Ahead of Year-End PREDICT-1 Readout

    Question

    Oculis to Present Licaminlimab at Eyecelerator Ahead of Year-End PREDICT-1 Readout

    Direct answer

    Biopharmaceutical developer Oculis announced that Chief Executive Officer Riad Sherif is scheduled to present the therapeutic profile of Licaminlimab at the Eyecelerator @ AAO 2026 meeting on October 8. The topical anti-TNF candidate addresses dry eye disease with genetic TNFR1 association. The company reaffirmed that the ongoing PREDICT-1 registrational trial is scheduled to deliver topline clinical readouts near year-end 2026.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Oculis to Present Licaminlimab at Eyecelerator Ahead of Year-End PREDICT-1 Readout”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/oculis-to-present-licaminlimab-at-eyecelerator-ahead-of-year-end-predict-1-reado-36498a

    EQUITY
    Oculis to Present Licaminlimab at Eyecelerator Ahead of Year-End PREDICT-1 Readout
    Biopharmaceutical developer Oculis announced that Chief Executive Officer Riad Sherif is scheduled to present the therapeutic profile of Licaminlimab at the Eyecelerator @ AAO 2026 meeting on October 8. The topical anti-TNF candidate addresses dry eye disease with genetic TNFR1 association. The company reaffirmed that the ongoing PREDICT-1 registrational trial is scheduled to deliver topline clinical readouts near year-end 2026.
    OCS
    Impact
    54
    OCT 7
    SIG
    85%
    OCS
    Oculis to Present Licaminlimab at Eyecelerator Ahead of Year-End PREDICT-1 Readout
    Biopharmaceutical developer Oculis announced that Chief Executive Officer Riad Sherif is scheduled to present the therapeutic profile of Licaminlimab at the Eyecelerator @ AAO 2026 meeting on October 8. The topical anti-TNF candidate addresses dry eye disease with genetic TNFR1 association. The company reaffirmed that the ongoing PREDICT-1 registrational trial is scheduled to deliver topline clinical readouts near year-end 2026.
    → Clinical trial milestone updates for novel ophthalmic biologic formulations drive asset valuation repricing ahead of pivotal registrational readouts.
    Impact
    Biopharmaceutical developer Oculis announced that Chief Executive Officer Riad Sherif is scheduled to present the therapeutic profile of Licaminlimab at the Eyecelerator @ AAO 2026 meeting on October 8. The topical anti-TNF candidate addresses dry eye disease with genetic TNFR1 association. The company reaffirmed that the ongoing PREDICT-1 registrational trial is scheduled to deliver topline clinical readouts near year-end 2026.
    Affected
    OCS
    Transmission
    Clinical trial milestone updates for novel ophthalmic biologic formulations drive asset valuation repricing ahead of pivotal registrational readouts.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    OCSclinical pipeline milestone progress and trial catalyst timingUp1-3mOculis confirmed PREDICT-1 registrational readout around year-end 2026 ahead of Oct 8 presentation.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month